SCHEMBL3144642

SCHEMBL3144642

COc1cc(Cl)ccc1Oc1ccccc1NS(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 10/20 0.62
CCR1 P32246 3/20 0.62
ALDH1A1 P00352 2/20 0.57
POLB P06746 1/20 0.57
CCR5 P51681 2/20 0.56
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
CCR4 P51679 1/20 0.55
KCNH2 Q12809 1/20 0.55
NPC1 O15118 1/20 0.55
TSHR P16473 1/20 0.55
TTR P02766 1/20 0.53
TP53 P04637 1/20 0.53
RAD52 P43351 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3052654 0.88 CCR2 (0.66) CCR2CCR1CCR5CYP1A2CYP3A4
SCHEMBL3148207 0.84 CCR2 (0.55) CCR2CCR1POLBCCR5CYP2C9
SCHEMBL164916 0.84 LMNA (0.72) CCR2CCR1ALDH1A1CCR5CYP2C9
SCHEMBL8711266 0.84 POLB (0.78) ALDH1A1POLBRAD52
SCHEMBL3148243 0.82 CCR2 (0.70) CCR2CCR1CCR5
SCHEMBL3055014 0.81 CCR2 (0.64) CCR2CCR1CCR5CYP1A2CYP3A4
SCHEMBL3157182 0.80 CCR2 (0.70) CCR2ALDH1A1KCNH2TSHR
SCHEMBL3049201 0.80 CCR2 (0.57) CCR2CCR1CCR5CYP1A2CYP3A4
SCHEMBL3046348 0.79 CCR2 (0.59) CCR2CCR1ALDH1A1CCR5CYP2C9
SCHEMBL6860342 0.79 CCR2 (0.64) CCR2CCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP disclosed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 CCR2 417/4885CCR1 358/4885ALDH1A1 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.